1. Ernster L, Dallner G. (1997): „Biochemical, physiological and medical aspects of ubiquinone function.“. Biochim Biophys Acta. 1995;1271(1):195-204. (PubMed)

2. Crane FL. (2001): „Biochemical functions of coenzyme Q10.“. J Am Coll Nutr. 2001;20(6):591-598. (PubMed)

3. Nohl H, Gille L. (2001): „The role of coenzyme Q in lysosomes.“ In: Kagan VEQ, P. J. (ed). Coenzyme Q: Molecular Mechanisms in Health and Disease. Boca Raton: CRC Press; 2001:99-106.

4. Thomas SR, Stocker R. (2001): „Mechanisms of antioxidant action of ubiquinol-10 for low-density lipoprotein.“ In: Kagan VE, Quinn PJ,eds. Coenzyme Q: Molecular Mechanisms in Health and Disease. Boca Raton: CRC Press; 2001:131-150.

5. Kagan VE, Fabisak JP, Tyurina YY. (2001): „Independent and concerted antioxidant functions of coenzyme Q.“. In: Kagan VE, Quinn PJ,eds. Coenzyme Q: Molecular Mechanisms in Health and Disease. Boca Raton: CRC Press; 2001:119-130.

6. Willis R, Anthony M, Sun L, Honse Y, Qiao G. (1999): „Clinical implications of the correlation between coenzyme Q10 and vitamin B6 status.“. Biofactors. 1999;9(2-4):359-363. (PubMed)

7. Overvad K, Diamant B, Holm L, Holmer G, Mortensen SA, Stender S. (1999): „Coenzyme Q10 in health and disease.“. Eur J Clin Nutr. 1999;53(10):764-770.(PubMed)

8. Weber C. Dietary intake and absorption of coenzyme Q. In: Kagan VE, Quinn PJ,eds. (2001): „Coenzyme Q: Molecular Mechanisms in Health and Disease.“. Boca Raton: CRC Press; 2001:209-215.

9. Mattila P, Kumpulainen J. (2001): „Coenzymes Q9 and Q10: Contents in foods and dietary intake.“. J Food Comp Anal. 2001;14(4):409-417.

10. Kamei M, Fujita T, Kanbe T, et al. (1986): „The distribution and content of ubiquinone in foods.“. Int J Vitam Nutr Res. 1986;56(1):57-63. (PubMed)

11. Weber C, Bysted A, Holmer G. (1997): „Coenzyme Q10 in the diet--daily intake and relative bioavailability.“. Mol Aspects Med. 1997;18 Suppl:S251-254. (PubMed)

12. Shults CW, Flint Beal M, Song D, Fontaine D. (2004): „Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease.“. Exp Neurol. 2004;188(2):491-494. (PubMed)

13. Hendler SS, Rorvik DR (eds). (2001): „PDR for Nutritional Supplements.“. Montvale: Medical Economics Company, Inc; 2001.

14. Mohr D, Bowry VW, Stocker R. (1992): „Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation.“. Biochim Biophys Acta. 1992;1126(3):247-254. (PubMed)

15. Singh RB, Niaz MA, Kumar A, Sindberg CD, Moesgaard S, Littarru GP. (2005): „Effect on absorption and oxidative stress of different oral Coenzyme Q10 dosages and intake strategy in healthy men.“. Biofactors. 2005;25(1-4):219-224.(PubMed)

16. Lonnrot K, Holm P, Lagerstedt A, Huhtala H, Alho H. (1998): „The effects of lifelong ubiquinone Q10 supplementation on the Q9 and Q10 tissue concentrations and life span of male rats and mice.“. Biochem Mol Biol Int. 1998;44(4):727-737. (PubMed)

17. Zhang Y, Aberg F, Appelkvist EL, Dallner G, Ernster L. (1995): „Uptake of dietary coenzyme Q supplement is limited in rats.“. J Nutr. 1995;125(3):446-453.(PubMed)

18. Svensson M, Malm C, Tonkonogi M, Ekblom B, Sjodin B, Sahlin K. (1999): „Effect of Q10 supplementation on tissue Q10 levels and adenine nucleotide catabolism during high-intensity exercise.“. Int J Sport Nutr. 1999;9(2):166-180. (PubMed)

19. Matthews RT, Yang L, Browne S, Baik M, Beal MF. (1998): „Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects.“. Proc Natl Acad Sci U S A. 1998;95(15):8892-8897.(PubMed)

20. Rosenfeldt FL, Pepe S, Linnane A, et al. (2002): „The effects of ageing on the response to cardiac surgery: protective strategies for the ageing myocardium.“. Biogerontology. 2002;3(1-2):37-40. (PubMed)

21. Kalen A, Appelkvist EL, Dallner G. (1989): „Age-related changes in the lipid compositions of rat and human tissues. Lipids.“. 1989;24(7):579-584.(PubMed)

22. Beckman KB, Ames BN. (1998): „Mitochondrial aging: open questions.“. Ann N Y Acad Sci. 1998;854:118-127. (PubMed)

23. Alho H, Lonnrot K. (2001): „Coenzyme Q supplementation and longevity.“. In: Kagan VE, Quinn PJ,eds. Coenzyme Q: Molecular Mechanisms in Health and Disease. Boca Raton: CRC Press; 2001:371-380.

24. Sohal RS, Kamzalov S, Sumien N, et al. (2006): „Effect of coenzyme Q10 intake on endogenous coenzyme Q content, mitochondrial electron transport chain, antioxidative defenses, and life span of mice.“. Free Radic Biol Med. 2006;40(3):480-487. (PubMed)

25. Quiles JL, Ochoa JJ, Battino M, et al. (2005): „Life-long supplementation with a low dosage of coenzyme Q10 in the rat: effects on antioxidant status and DNA damage.“. Biofactors. 2005;25(1-4):73-86. (PubMed)

26. Witting PK, Pettersson K, Letters J, Stocker R. (2000): „Anti-atherogenic effect of coenzyme Q10 in apolipoprotein E gene knockout mice.“. Free Radic Biol Med. 2000;29(3-4):295-305. (PubMed)

27. Thomas SR, Leichtweis SB, Pettersson K, et al. (2001): „Dietary cosupplementation with vitamin E and coenzyme Q(10) inhibits atherosclerosis in apolipoprotein E gene knockout mice.“. Arterioscler Thromb Vasc Biol. 2001;21(4):585-593.(PubMed)

28. Turunen M, Wehlin L, Sjoberg M, et al. (2002): „beta2-Integrin and lipid modifications indicate a non-antioxidant mechanism for the anti-atherogenic effect of dietary coenzyme Q10.“. Biochem Biophys Res Commun. 2002;296(2):255-260. (PubMed)

29. Shoffner JM. (2001): „Oxidative phosphorylation diseases.“. In: Scriver CR, Beaudet AL, Sly WS, Valle D,eds. The metabolic and molecular bases of inherited disease. 8th ed. Volume 2. New York: McGraw-Hill; 2001:2367-2392.

30. Rotig A, Appelkvist EL, Geromel V, et al. (2000): „Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency.“. Lancet. 2000;356(9227):391-395. (PubMed)

31. Boitier E, Degoul F, Desguerre I, et al. (1998): „A case of mitochondrial encephalomyopathy associated with a muscle coenzyme Q10 deficiency.“. J Neurol Sci. 1998;156(1):41-46. (PubMed)

32. Munnich A, Rotig A, Cormier-Daire V, Rustin P. (2001): „Clinical presentation of respiratory chain deficiency.“. In: Scriver CR, Beaudet AL, Sly WS, Valle D,eds. The metabolic and molecular bases of inherited disease. 8th ed. Volume 2. New York: McGraw-Hill; 2001:2261-2274.

33. Trupp RJ, Abraham WT. (2002): „Congestive heart failure.“. In: Rakel RE, Bope ET,eds. Rakel: Conn's Current Therapy 2002. 54th ed. New York: W. B. Saunders Company; 2002:306-313.

34. Folkers K, Vadhanavikit S, Mortensen SA. (1985): „Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10.“. Proc Natl Acad Sci U S A. 1985;82(3):901-904. (PubMed)

35. Belardinelli R, Mucaj A, Lacalaprice F, et al. (2006): „Coenzyme Q10 and exercise training in chronic heart failure.“. Eur Heart J. 2006. (PubMed)

36. Tran MT, Mitchell TM, Kennedy DT, Giles JT. (2001): „Role of coenzyme Q10 in chronic heart failure, angina, and hypertension.“. Pharmacotherapy. 2001;21(7):797-806. (PubMed)

37. Belardinelli R, Mucaj A, Lacalaprice F, et al. (2005): „Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure.“. Biofactors. 2005;25(1-4):137-145. (PubMed)

38. Khatta M, Alexander BS, Krichten CM, et al. (2000): „The effect of coenzyme Q10 in patients with congestive heart failure.“. Ann Intern Med. 2000;132(8):636-640.(PubMed)

39. Watson PS, Scalia GM, Galbraith A, Burstow DJ, Bett N, Aroney CN. (1999): „Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure.“. J Am Coll Cardiol. 1999;33(6):1549-1552. (PubMed)

40. Lonnrot K, Tolvanen JP, Porsti I, Ahola T, Hervonen A, Alho H. (1999): „Coenzyme Q10 supplementation and recovery from ischemia in senescent rat myocardium.“. Life Sci. 1999;64(5):315-323. (PubMed)

41. Maulik N, Yoshida T, Engelman RM, Bagchi D, Otani H, Das DK. (2000): „Dietary coenzyme Q(10) supplement renders swine hearts resistant to ischemia-reperfusion injury.“. Am J Physiol Heart Circ Physiol. 2000;278(4):H1084-1090.(PubMed)

42. Langsjoen PH, Langsjoen AM. (1999): „Overview of the use of CoQ10 in cardiovascular disease.“. Biofactors. 1999;9(2-4):273-284. (PubMed)

43. Taggart DP, Jenkins M, Hooper J, et al. (1996): „Effects of short-term supplementation with coenzyme Q10 on myocardial protection during cardiac operations.“. Ann Thorac Surg. 1996;61(3):829-833. (PubMed)

44. Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. (1999): „Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease.“. J Hum Hypertens. 1999;13(3):203-208. (PubMed)

45. Burke BE, Neuenschwander R, Olson RD. (2001): „Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension.“. South Med J. 2001;94(11):1112-1117. (PubMed)

46. Ross R. (1999): „Atherosclerosis--an inflammatory disease.“. N Engl J Med. 1999;340(2):115-126. (PubMed)

47. Watts GF, Playford DA, Croft KD, Ward NC, Mori TA, Burke V. (2002): „Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus.“. Diabetologia. 2002;45(3):420-426. (PubMed)

48. Raitakari OT, McCredie RJ, Witting P, et al. (2000): „Coenzyme Q improves LDL resistance to ex vivo oxidation but does not enhance endothelial function in hypercholesterolemic young adults.“. Free Radic Biol Med. 2000;28(7):1100-1105. (PubMed)

49. Kuettner A, Pieper A, Koch J, Enzmann F, Schroeder S. (2005): „Influence of coenzyme Q(10) and cerivastatin on the flow-mediated vasodilation of the brachial artery: results of the ENDOTACT study.“. Int J Cardiol. 2005;98(3):413-419. (PubMed)

50. McDonnell MG, Archbold GP. (1996): „Plasma ubiquinol/cholesterol ratios in patients with hyperlipidaemia, those with diabetes mellitus and in patients requiring dialysis.“. Clin Chim Acta. 1996;253(1-2):117-126. (PubMed)

51. Henriksen JE, Andersen CB, Hother-Nielsen O, Vaag A, Mortensen SA, Beck-Nielsen H. (1999): „Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, insulin requirement and well-being in patients with Type 1 diabetes mellitus.“. Diabet Med. 1999;16(4):312-318. (PubMed)

52. Eriksson JG, Forsen TJ, Mortensen SA, Rohde M. (1999): „The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus.“. Biofactors. 1999;9(2-4):315-318. (PubMed)

53. Alcolado JC, Laji K, Gill-Randall R. (2002): „Maternal transmission of diabetes.“. Diabet Med. 2002;19(2):89-98. (PubMed)

54. SSuzuki S, Hinokio Y, Ohtomo M, et al. (1998): „The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation.“. Diabetologia. 1998;41(5):584-588.(PubMed)

55. Gotz ME, Gerstner A, Harth R, et al. (2000): „Altered redox state of platelet coenzyme Q10 in Parkinson's disease.“. J Neural Transm. 2000;107(1):41-48.(PubMed)

56. Shults CW, Haas RH, Passov D, Beal MF. (1997): „Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects.“. Ann Neurol. 1997;42(2):261-264. (PubMed)

57. Shults CW, Oakes D, Kieburtz K, et al. (2002): „Effects of coenzyme q10 in early Parkinson disease: evidence of slowing of the functional decline.“. Arch Neurol. 2002;59(10):1541-1550. (PubMed)

58. Muller T, Buttner T, Gholipour AF, Kuhn W. (2003): „Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease.“. Neurosci Lett. 2003;341(3):201-204. (PubMed)

59. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. (1997): „Energy metabolism defects in Huntington's disease and effects of coenzyme Q10.“. Ann Neurol. 1997;41(2):160-165. (PubMed)

60. Beal MF. (2002): „Coenzyme Q10 as a possible treatment for neurodegenerative diseases.“. Free Radic Res. 2002;36(4):455-460. (PubMed)

61. Ferrante RJ, Andreassen OA, Dedeoglu A, et al. (2002): „Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.“. J Neurosci. 2002;22(5):1592-1599. (PubMed)

62. Schilling G, Coonfield ML, Ross CA, Borchelt DR. (2001): „Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model.“. Neurosci Lett. 2001;315(3):149-153. (PubMed)

63. Stack EC, Kubilus JK, Smith K, et al. (2005): „Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice.“. J Comp Neurol. 2005;490(4):354-370. (PubMed)

64. Stack EC, Smith KM, Ryu H, et al. (2006): „Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice.“. Biochim Biophys Acta. 2006;1762(3):373-380. (PubMed)

65. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology. 2001;57(3):397-404. (PubMed)

66. Gatchel JR, Zoghbi HY. (2005): „Diseases of unstable repeat expansion: mechanisms and common principles.“. Nat Rev Genet. 2005;6(10):743-755.(PubMed)

67. Cooper JM, Schapira AH. (2003): „Friedreich's Ataxia: disease mechanisms, antioxidant and Coenzyme Q10 therapy.“. Biofactors. 2003;18(1-4):163-171.(PubMed)

68. Taroni F, DiDonato S. (2004): „Pathways to motor incoordination: the inherited ataxias.“. Nat Rev Neurosci. 2004;5(8):641-655. (PubMed)

69. Lodi R, Tonon C, Calabrese V, Schapira AH. (2006): „Friedreich's ataxia: from disease mechanisms to therapeutic interventions.“. Antioxid Redox Signal. 2006;8(3-4):438-443. (PubMed)

70. Lodi R, Hart PE, Rajagopalan B, et al. (2001): „Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia.“. Ann Neurol. 2001;49(5):590-596. (PubMed)

71. Hart PE, Lodi R, Rajagopalan B, et al. (2005): „Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.“. Arch Neurol. 2005;62(4):621-626.(PubMed)

72. Folkers K, Osterborg A, Nylander M, Morita M, Mellstedt H. (1997): „Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer.“. Biochem Biophys Res Commun. 1997;234(2):296-299. (PubMed)

73. Hodges S, Hertz N, Lockwood K, Lister R. (1992): „CoQ10: could it have a role in cancer management?“. Biofactors. 1999;9(2-4):365-370. (PubMed)

74. Laaksonen R, Fogelholm M, Himberg JJ, Laakso J, Salorinne Y. (1995): „Ubiquinone supplementation and exercise capacity in trained young and older men.“. Eur J Appl Physiol Occup Physiol. 1995;72(1-2):95-100. (PubMed)

75. Malm C, Svensson M, Ekblom B, Sjodin B. (1997): „Effects of ubiquinone-10 supplementation and high intensity training on physical performance in humans.“. Acta Physiol Scand. 1997;161(3):379-384. (PubMed)

76. Weston SB, Zhou S, Weatherby RP, Robson SJ. (1997): „Does exogenous coenzyme Q10 affect aerobic capacity in endurance athletes?“. Int J Sport Nutr. 1997;7(3):197-206. (PubMed)

77. Porter DA, Costill DL, Zachwieja JJ, et al. (1995): „The effect of oral coenzyme Q10 on the exercise tolerance of middle-aged, untrained men.“. Int J Sports Med. 1995;16(7):421-427. (PubMed)

78. Braun B, Clarkson PM, Freedson PS, Kohl RL. (1991): „Effects of coenzyme Q10 supplementation on exercise performance, VO2max, and lipid peroxidation in trained cyclists.“. Int J Sport Nutr. 1991;1(4):353-365. (PubMed)

79. Bonetti A, Solito F, Carmosino G, Bargossi AM, Fiorella PL. (2000): „Effect of ubidecarenone oral treatment on aerobic power in middle-aged trained subjects.“. J Sports Med Phys Fitness. 2000;40(1):51-57. (PubMed)

80. Hathcock JN, Shao A. (2006): „Risk assessment for coenzyme Q10 (Ubiquinone).“. Regul Toxicol Pharmacol. 2006;45(3):282-288. (PubMed)

81. Jellin JM. (2002): „Natural Medicines Comprehensive Database.“. Therapeutic Research Faculty. Available at: www.naturaldatabase.com. Accessed 11/07/02, 2002.

82. Heck AM, DeWitt BA, Lukes AL. (2000): „Potential interactions between alternative therapies and warfarin.“. Am J Health Syst Pharm. 2000;57(13):1221-1227; quiz 1228-1230. (PubMed)

83. Folkers K, Langsjoen P, Willis R, et al. (1990): „Lovastatin decreases coenzyme Q levels in humans.“. Proc Natl Acad Sci U S A. 1990;87(22):8931-8934. (PubMed)

84. Colquhoun DM, Jackson R, Walters M, et al. (2005): „Effects of simvastatin on blood lipids, vitamin E, coenzyme Q10 levels and left ventricular function in humans.“. Eur J Clin Invest. 2005;35(4):251-258. (PubMed)

85. Mabuchi H, Higashikata T, Kawashiri M, et al. (2005): „Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients.“. J Atheroscler Thromb. 2005;12(2):111-119.(PubMed)

86. Bargossi AM, Battino M, Gaddi A, et al. (1994): „Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.“. Int J Clin Lab Res. 1994;24(3):171-176.(PubMed)

87. Watts GF, Castelluccio C, Rice-Evans C, Taub NA, Baum H, Quinn PJ. (1993): „Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin.“. J Clin Pathol. 1993;46(11):1055-1057. (PubMed)

88. Ghirlanda G, Oradei A, Manto A, et al. (1993): „Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study.“. J Clin Pharmacol. 1993;33(3):226-229. (PubMed)

89. Laaksonen R, Jokelainen K, Laakso J, et al. (1996): „The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle.“. Am J Cardiol. 1996;77(10):851-854. (PubMed)

90. Laaksonen R, Ojala JP, Tikkanen MJ, Himberg JJ. (1994): „Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors.“. Eur J Clin Pharmacol. 1994;46(4):313-317. (PubMed)

91. Elmberger PG, Kalen A, Lund E, et al. (1991): „Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia.“. J Lipid Res. 1991;32(6):935-940. (PubMed)

92. Hughes K, Lee BL, Feng X, Lee J, Ong CN. (2002): „Coenzyme Q10 and differences in coronary heart disease risk in Asian Indians and Chinese.“. Free Radic Biol Med. 2002;32(2):132-138. (PubMed)

93. Hargreaves IP, Duncan AJ, Heales SJ, Land JM. (2005): „The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications.“. Drug Saf. 2005;28(8):659-676. (PubMed)

94. Laaksonen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg JJ. (1997): „Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans.“. Clin Pharmacol Ther. 1995;57(1):62-66. (PubMed)

Nach oben